Back to Search
Start Over
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia
- Source :
- Blood advances. 3(21)
- Publication Year :
- 2019
-
Abstract
- Key Points This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal T-PLL.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
T cell
Biopsy
Immunophenotyping
03 medical and health sciences
0302 clinical medicine
Antineoplastic Agents, Immunological
Refractory
Internal medicine
Meningeal Neoplasms
Medicine
Combined Modality Therapy
Neoplasm
Humans
Molecular Targeted Therapy
Alemtuzumab
Injections, Spinal
business.industry
Hematology
Middle Aged
medicine.disease
Blood Cell Count
Leukemia
030104 developmental biology
medicine.anatomical_structure
Treatment Outcome
Drug Resistance, Neoplasm
Leukemia, Prolymphocytic, T-Cell
Retreatment
T-cell prolymphocytic leukemia
Female
Exceptional Case Report
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 24739537
- Volume :
- 3
- Issue :
- 21
- Database :
- OpenAIRE
- Journal :
- Blood advances
- Accession number :
- edsair.doi.dedup.....0b1fdff769652eef09d7d173928cdde3